Japan-based Astellas has promoted David Abbott as its national vice president, Key Account Management, it was announced yesterday.
Abbott's earlier role was senior director of Key Account Management for the company's Oncology franchise. Based in Massachusetts, Abbott has more than 20 years of biopharma experience, previously serving as national access director at AVEO Oncology. He also worked at Sanofi and Sanofi Genzyme, including as regional sales manager for Hospital and Oncology, Oncology Access & Reimbursement account manager, and director of Multiple Sclerosis Payer and Channel Marketing. Abbott joined Astellas in 2013.
Abbott will now manage teams who work with large healthcare organizations to provide educational resources and tools that help customers identify, educate and treat patients.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval